August 2022 A NanoBRET-Based H 3 R Conformational Biosensor to Study Real-Time H 3 Receptor Pharmacology

April 2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare disorders, today announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing)."

biosensors reveals distinct conformational signatures of β-arrestin1 and 2 when bound to active PTH1R (P-R* specifically by proximal and distal C-terminal phosphorylation and in the absence of GPCR kinases (GRKs) (R* Here, we show differences between conformational changes that are induced by P-R* or R* receptor states

Authors Charles H Williams , Leif R Neitzel , Jessica Cornell , Samantha Rea , Ian Mills , Maya S Silver

GPCR Podcast << Back to podcast list Scott Struthers R. R. Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr.

with decitabine (DAC) demonstrated initial safety and efficacy in patients with relapsed/refractory (R/ R) AML. The current study aimed to identify molecular predictors of response to ONV + DAC in R/R AML patients A total of 44 R/R AML patients were treated with ONV + DAC and considered evaluable for efficacy. PLK1 inhibition with ONV in combination with DAC could be a potential therapy in R/R AML patients, particularly